Skip to main content

Keynote B84 A phase 1b/2 Study of the Combination of Pepinemab and Pembrolizumab in Patients with Advanced, Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck.

NCT0140603

A phase 1b/2 Study of the Combination of Pepinemab and Pembrolizumab in Patients with Advanced, Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck.

Associated Conditions

Head and Neck Cancer

Principal Investigator

Sponsor

Vaccinex Inc